Skip to main content

How can we help you?

  • 03-10-2013

On 27 August 2013, the Court of Appeal of The Hague rendered a remarkable judgment in preliminary injunction proceedings between Teva and Sanofi. These proceedings concern two SPCs held by Sanofi that were issued for (i) irbesartan - marketed under the name Aprovel - and (ii) a combination product comprising irbesartan and hydrochlorothiazide ("HCTZ") - marketed under the name Co-Aprovel. Both SPC's are based on the same basic patent. This basic patent for the class of compounds to which irbesartan belongs, also contains a claim relating to irbesartan and “a diuretic”.

Please read more on this topic in our newsletter.

Cookie notice

We care about your privacy. We only use cookies strictly necessary to ensure the proper functioning of our website. You can find more information on cookies and on how we handle your personal data in our Privacy and Cookie Policy.